Every successful pregnancy requires proper embryo implantation. Low implantation rate is a major problem during infertility treatments using assisted reproductive technologies 1 . Here we report a newly discovered molecular influence on implantation through the lysophosphatidic acid (LPA) receptor LPA 3 (refs 2-4). Targeted deletion of LPA 3 in mice resulted in significantly reduced litter size, which could be attributed to delayed implantation and altered embryo spacing. These two events led to delayed embryonic development, hypertrophic placentas shared by multiple embryos and embryonic death. An enzyme demonstrated to influence implantation, cyclooxygenase 2 (COX2) (ref. 5) , was downregulated in LPA 3 -deficient uteri during preimplantation. Downregulation of COX2 led to reduced levels of prostaglandins E 2 and I 2 (PGE 2 and PGI 2 ), which are critical for implantation 1 . Exogenous administration of PGE 2 or carbaprostacyclin (a stable analogue of PGI 2 ) into LPA 3 -deficient female mice rescued delayed implantation but did not rescue defects in embryo spacing. These data identify LPA 3 receptormediated signalling as having an influence on implantation, and further indicate linkage between LPA signalling and prostaglandin biosynthesis.
Multiple factors can adversely affect successful pregnancy. Two of these factors are failed synchronization between embryonic and endometrial development during implantation and occurrence of multiple gestations (especially monochorionic gestation), which can result in fetal demise 1, [6] [7] [8] [9] . These factors are particularly important for the clinical success and efficacy of assisted reproductive technologies. One molecular factor that has been previously implicated in female reproduction is the small, bioactive phospholipid LPA 10 . LPA has a range of influences that are mediated by at least four G-protein-coupled receptors, LPA 1-4 (ref. 2) . Deletion of LPA 1 and LPA 2 in mice revealed roles for these receptors in neural development, craniofacial formation, neuropathic pain and altered cellular signalling, but without obvious effects on female reproduction [11] [12] [13] [14] . These results suggested that LPA signalling in female reproduction might be mediated by other LPA receptors including LPA 3 (formerly known as Edg7) (refs 3, 4), LPA 4 (ref. 15) , unidentified LPA receptor(s), or possibly non-receptor pathways. Towards identifying LPA-dependent mechanisms affecting reproduction, we targeted LPA 3 for deletion. LPA 3 is a receptor with distinct signalling properties and a preference for unsaturated LPA species [2] [3] [4] . Functional deletion of LPA 3 was achieved by replacing a fragment covering the untranslated region and the start codon in exon 2 with a neomycin-resistance gene in reverse orientation in R1 embryonic stem cells ( Supplementary Figs 1 and 2 ). The LPA 3 -deficient mice were born with normal mendelian frequency without sexual bias (Supplementary Table 1) , and appeared grossly normal (data not shown). However, LPA 3 -deficient females produced litter sizes of less than 50% compared with that of wild-type and LPA 3 heterozygote controls (Supplementary Table 2 ), and showed a statistically significant prolongation of pregnancy (20.9^0.5 days versus 19.4^0.7 days in wild-type and LPA 3 heterozygote controls, P , 0.05). These phenotypes were independent of stud genotype, indicating defects in female reproduction.
Towards determining whether LPA 3 deletion might directly affect the female reproductive system, expression patterns of LPA 3 messenger RNA were assessed using polymerase chain reaction with reverse transcription (RT-PCR) and in situ hybridization. RT-PCR revealed the presence of LPA 3 mRNA in oviduct, placenta and uterus but not in ovary and eggs (unfertilized eggs and fertilized eggs from one cell to pre-implantation blastocyst; data not shown). Within the uterus, LPA 3 mRNA expression was upregulated during postnatal development and varied during the oestrous cycle (Supplementary Fig. 3a, b) . Notably, LPA 3 mRNA levels increased during early pregnancy, peaking around embryonic day 3.5 (E3.5) then returning to basal levels from E4.5 through to the end of pregnancy (Fig. 1a) . RT-PCR of microdissected E3.5 uterine tissue and in situ hybridization indicated that LPA 3 mRNA expression was confined to the luminal endometrial epithelium at E3.5 ( Fig. 1b-d ; see also Supplementary Fig. 3c ). These data suggested that LPA 3 loss of function resulting in reduced litter sizes could involve direct effects on the female reproductive system.
To explore this possibility, we examined major events in female reproduction: from ovulation through to decidualization. No significant differences were observed in superovulation, fertilization or decidualization between wild-type or LPA 3 heterozygote controls and LPA 3 -deficient female littermates. No significant differences in blastocyst number or developmental stage, isolated from E3.5 uteri, were observed between control and LPA 3 -deficient females. These data indicated no obvious defects in ovulation, ovum transportation and blastocyst development in LPA 3 -deficient female mice ( Fig. 1e ; see also Supplementary Fig. 4 ).
In contrast, embryo implantation studies identified clear phenotypic changes in LPA 3 -deficient dams: delayed implantation and altered positioning/crowding of embryos. By E4.5, implantation sites identifiable by Evans blue labelling in control animals were absent in uteri of LPA 3 -deficient dams. Implantation sites became detectable at E5.5 in uteri of LPA 3 -deficient mice (Fig. 1f, g ) 16 . The number of pre-implantation blastocysts recovered from E4.5 LPA 3 -deficient uteri was comparable to that from E3.5 control and LPA 3 -deficient uteri (Fig. 1e) , indicating that delayed implantation in uteri of LPA 3 -deficient mice was due to extra-embryonic influences of LPA signalling. In addition to delayed implantation, LPA 3 -deficient uteri had a reduced number of implantation sites compared with that in the control uteri, despite the fact that comparable numbers of blastocysts were available for implantation. The implantation sites in the LPA 3 -deficient uteri were crowded/ clustered in the uterine segments proximal to the cervix (Fig. 1g) . This aberrant crowding of embryos in uteri of LPA 3 -deficient mice was further demonstrated by findings at later gestational stages. At E10.5, 44% of implantation sites in LPA 3 -deficient uteri contained two to four embryos (averaging 1.65 live embryos per implantation site) (Fig. 2a, b) . At E18.5, 28% of placentas were shared by two to three embryos (Fig. 2c) and associated with placental hypertrophy ( Fig. 2d ; see also Supplementary Fig. 5 ). These phenomena were never observed in controls.
In addition, embryos isolated from LPA 3 -deficient uteri (at E10.5 and E18.5) were always smaller than those from wild-type or LPA 3 heterozygote controls at comparable ages (Fig. 3a-c) , although newborns from LPA 3 -deficient females were, on average, heavier (Fig. 3c) , possibly resulting from prolonged pregnancy and/or smaller litter size. The average number of live embryos per animal that could be isolated from LPA 3 -deficient females decreased after initial implantation (Fig. 3d) . Delayed implantation and aberrant embryo spacing were thus associated with both delayed embryonic development and embryonic death, which could account for the reduced litter sizes produced by LPA 3 -deficient females.
To determine whether LPA 3 loss in the embryo itself might contribute to the phenotypes, embryo transfer experiments were pursued. Wild-type blastocysts were transferred to wild-type or LPA 3 -deficient pseudo-pregnant uteri. Transferred wild-type embryos in wild-type or LPA 3 -deficient pseudo-pregnant uteri were phenotypically indistinguishable for implantation and development compared to embryos produced by natural matings in wild-type or LPA 3 -deficient animals. Similarly, when LPA 3 -deficient blastocysts were transferred to wild-type pseudo-pregnant uteri, no implantation or spacing abnormalities were observed (Supplementary Fig. 6 and data not shown). Wild-type and LPA 3 -deficient blastocysts had comparable implantation rates in wild-type pseudo-pregnant uteri. Considering the fact that no LPA 3 mRNA was detected in wild-type pre-implantation blastocysts, these results eliminate significant contributions of LPA 3 via pre-/post-implantation embryos, and indicate that maternal LPA 3 signalling is responsible for the observed phenotypes.
The observed implantation phenotypes of LPA 3 -deficient mice were markedly similar to those reported for rats and mice treated with indomethacin 17, 18 , and for mice deficient in cytosolic phospholipase A 2a (cPLA 2a ) 19 . Indomethacin is an inhibitor of cyclooxygenases 20 , which convert arachidonic acid to prostaglandin H 2 (PGH 2 ) in the biosynthesis of prostaglandins, whereas cPLA 2a is an important enzyme producing arachidonic acid. Notably, COX2 deficiency, but not COX1 deficiency, in mice results in multiple female reproductive failures, including implantation defects 5, 21 , although the precise phenotypes can be influenced by genetic background 22, 23 . Moreover, PGE 2 and carbaprostacyclin (cPGI, a stable analogue of PGI 2 ) can partially correct implantation defects in both cPLA 2a -deficient and COX2-deficient mice 19, 24 . These data indicate that the cPLA 2a -arachidonic acid-COX-prostaglandin pathway is crucial for implantation 1 . In view of the phenotypic similarities between LPA 3 deficiency and cPLA 2a /prostaglandin deficiency, we proposed that LPA 3 might converge on this signalling pathway.
Components of prostaglandin signalling were therefore examined in uteri of LPA 3 -deficient mice. These components included cPLA 2a , COX1 and COX2, and G-protein-coupled prostaglandin E 2 receptors EP 1-4 and prostaglandin I 2 receptor, IP 25 , along with leukaemia inhibitory factor (LIF) and Hoxa-10, two key regulators in implantation 1 . Only COX2 mRNA levels were significantly reduced in LPA 3 -deficient uteri (Fig. 4a, Supplementary Fig. 7 , and data not shown). COX2 is a rate-limiting enzyme for prostaglandin biosynthesis. Consistent with this function, the suppression of COX2 expression in E3.5 LPA 3 -deficient uteri resulted in reduced production of PGE 2 and PGI 2 (Fig. 4b) , leading to conditions that are inadequate for implantation, which normally occurs around E4.0 (refs 18, 26) . To rescue this prostaglandin reduction, we delivered exogenous PGE 2 and cPGI to E3.5 LPA 3 -deficient female mice, a general approach previously reported 19 . After prostaglandin exposure, significantly more LPA 3 -deficient female mice with normal (on-time) implantation were detected compared with LPA 3 -deficient females given vehicle controls ( Fig. 4c , P ¼ 0.003). Notably, this rescue did not affect the uneven embryo spacing nor completely restore the reduction of implantation sites compared with wild-type controls (Figs 1g and 4d) .
These findings identify LPA signalling as having an influence on embryo implantation, and are the first to link a lysophospholipid G-protein-coupled receptor to prostaglandin biosynthesis, thereby influencing female fertility. As a class, lysophospholipid receptors represent a 'drugable' target, as demonstrated by the compound FTY720, which is currently in phase III clinical trials for prevention of transplantation rejection 27 . This raises the possibility of creating medicines that influence implantation timing, a critical factor for in vitro fertilization 1, 9 and also for reducing the incidence of multiembryo gestations, especially monochorionic gestations, which can result in fetal demise 6 . The reduced litter sizes observed in receptor-null mutants for another lysophospholipid, sphingosine 1-phosphate, suggest that other lysophospholipid receptors may also influence mammalian reproduction through pharmacologically tractable mechanisms 28 . A
Methods
Quantitative RT-PCR Primers used were as described 11, 12, 29 . For amplification of COX2, the following primers were used: forward 5 0 -AAGCGAGGACCTGGGTTCA-3 0 ; reverse, 5 0 -AAGGCGCAGTTT ATGTTGTCTGT-3 0 . Quantitative RT-PCR was performed as described 29 . The transcript number of target genes was quantified and normalized against GAPDH or b-actin transcript number.
In situ hybridization and histology
The animals were anaesthetized with halothane inhalation followed by cervical dislocation. In situ hybridization and histology were performed as described 30 . Sense and antisense DIG-labelled cRNA probes were generated using appropriate polymerases from a full-length murine LPA 3 complementary DNA.
Mating, embryo collection and implantation localization
All the mice used in this study were of mixed background (129/SvJ and C57BL/6). Because no difference was observed for all the parameters examined between wild-type and heterozygote female mice (Supplementary Table 2 , Supplementary Fig. 8a , b, and data not shown), females of either wild-type or heterozygote genotypes were used as controls. Females were naturally mated with wild-type stud males. The day a plug was found was designated as E0.5. Plugged females were anaesthetized with halothane inhalation followed by cervical dislocation. Uteri of pregnant females were dissected at E3.5, E4.5, E5.5, E10.5 and E18.5. Embryos at E10.5 were fixed in 10% formalin overnight before being weighed. Implantation sites at E4.5 and E5.5 were localized by intravenous injection of Evans blue dye (200 ml, 1% in 1 £ PBS, Sigma) 16 . The number of embryos initially implanted in LPA 3 -deficient and wild-type and heterozygote uteri were retrospectively calculated from E10.5 as follows: at E10.5, embryos in an average of 1.2 implantation sites (out of a total of 5.0) were absorbed in LPA 3 -deficient uteri, but embryos in only 0.09 implantation sites (out of a total of 8.4) were absorbed in wild-type and heterozygote uteri (P ¼ 1.7 £ 10 25 ). With an average of 1.65 live embryos per implantation site in LPA 3 -deficient uteri and 1.0 live embryo per implantation site in wild-type and heterozygote uteri at E10.5, the total number of embryos initially implanted should be 8.3 ((3.8 live þ 1.2 absorbed) £ 1.65) in LPA 3 -deficient uteri and 8.4 ((8.31 live þ 0.09 absorbed) £ 1.0) in wild-type and heterozygote uteri.
Prostaglandin measurement
Uteri from E3.5 wild-type or LPA 3 -deficient mice were immediately frozen and crushed in liquid nitrogen. Prostaglandins were extracted by the ethyl acetate extraction method. The prostaglandin levels of each sample were determined using the prostaglandin enzymelinked immunoassay kit (Cayman Chemical). PGI 2 was measured as 6-keto-PGF 1a .
Prostaglandin administration E3.5 LPA 3 -deficient females were intraperitoneally injected with 100 ml of vehicle (10% ETOH with saline, as control) or 5 mg cPGI and 5 mg PGE 2 (Cayman Chemical, in 10% ETOH with saline) at 10:00 and 18:00. Implantation sites were detected using Evans blue dye at E4.5.
Data representation
Data are expressed as mean^s.d. Statistical analyses were done using Student's t-test or x 2 test. The significance level was set at P , 0.05.
